Research ArticleOriginal Article

Glycolytic potential enhanced by blockade of pyruvate influx into mitochondria sensitizes prostate cancer to detection and radiotherapy

Huan Xu, Junyi Chen, Zhi Cao, Xi Chen, Caihong Huang, Jin Ji, Yalong Xu, Junfeng Jiang, Yue Wang, Guowang Xu, Lina Zhou, Jingyi He, Xuedong Wei, Jason Boyang Wu, Zhong Wang, Shancheng Ren and Fubo Wang
Cancer Biology & Medicine September 2022, 19 (9) 1315-1333; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0638

References

  1. 1.↵
    2. Hainaut P,
    3. Plymoth A.
    Cancer as a metabolic disease. Curr Opin Oncol. 2012; 24: 56–7.
    OpenUrlPubMed
  2. 2.↵
    2. Pavlova NN,
    3. Thompson CB.
    The emerging hallmarks of cancer metabolism. Cell Metab. 2016; 23: 27–47.
    OpenUrlCrossRefPubMed
  3. 3.↵
    2. Warburg O,
    3. Wind F,
    4. Negelein E.
    The metabolism of tumors in the body. J Gen Physiol. 1927; 8: 519–30.
    OpenUrlFREE Full Text
  4. 4.↵
    2. Martinez-Outschoorn UE,
    3. Peiris-Pages M,
    4. Pestell RG,
    5. Sotgia F,
    6. Lisanti MP.
    Cancer metabolism: a therapeutic perspective. Nat Rev Clin Oncol. 2017; 14: 11–31.
    OpenUrlCrossRefPubMed
  5. 5.↵
    2. DeBerardinis RJ,
    3. Chandel NS.
    Fundamentals of cancer metabolism. Sci Adv. 2016; 2: e1600200.
  6. 6.↵
    2. Eidelman E,
    3. Twum-Ampofo J,
    4. Ansari J,
    5. Siddiqui MM.
    The metabolic phenotype of prostate cancer. Front Oncol. 2017; 7: 131.
    OpenUrl
  7. 7.↵
    2. Elia I,
    3. Schmieder R,
    4. Christen S,
    5. Fendt SM.
    Organ-specific cancer metabolism and its potential for therapy. Handb Exp Pharmacol. 2016; 233: 321–53.
    OpenUrlCrossRefPubMed
  8. 8.↵
    2. Xu H,
    3. Chen J,
    4. He J,
    5. Ji J,
    6. Cao Z,
    7. Chen X, et al.
    Serum metabolic profiling identifies a biomarker panel for improvement of prostate cancer diagnosis. Front Oncol. 2021; 11: 666320.
  9. 9.↵
    2. Xu H,
    3. Chen Y,
    4. Gu M,
    5. Liu C,
    6. Chen Q,
    7. Zhan M, et al.
    Fatty acid metabolism reprogramming in advanced prostate cancer. Metabolites. 2021; 11: 765.
    OpenUrl
  10. 10.↵
    2. Herzig S,
    3. Raemy E,
    4. Montessuit S,
    5. Veuthey JL,
    6. Zamboni N,
    7. Westermann B, et al.
    Identification and functional expression of the mitochondrial pyruvate carrier. Science. 2012; 337: 93–6.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    2. Bricker DK,
    3. Taylor EB,
    4. Schell JC,
    5. Orsak T,
    6. Boutron A,
    7. Chen YC, et al.
    A mitochondrial pyruvate carrier required for pyruvate uptake in yeast, drosophila, and humans. Science. 2012; 337: 96–100.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    2. Bader DA,
    3. Hartig SM,
    4. Putluri V,
    5. Foley C,
    6. Hamilton MP,
    7. Smith EA, et al.
    Mitochondrial pyruvate import is a metabolic vulnerability in androgen receptor-driven prostate cancer. Nat Metab. 2019; 1: 70–85.
    OpenUrl
  13. 13.↵
    2. Corbet C,
    3. Bastien E,
    4. Draoui N,
    5. Doix B,
    6. Mignion L,
    7. Jordan BF, et al.
    Interruption of lactate uptake by inhibiting mitochondrial pyruvate transport unravels direct antitumor and radiosensitizing effects. Nat Commun. 2018; 9: 1208.
    OpenUrl
  14. 14.↵
    2. McCommis KS,
    3. Chen Z,
    4. Fu X,
    5. McDonald WG,
    6. Colca JR,
    7. Kletzien RF, et al.
    Loss of mitochondrial pyruvate carrier 2 in the liver leads to defects in gluconeogenesis and compensation via pyruvate-alanine cycling. Cell Metab. 2015; 22: 682–94.
    OpenUrlCrossRefPubMed
  15. 15.↵
    2. Yang C,
    3. Ko B,
    4. Hensley CT,
    5. Jiang L,
    6. Wasti AT,
    7. Kim J, et al.
    Glutamine oxidation maintains the TCA cycle and cell survival during impaired mitochondrial pyruvate transport. Mol Cell. 2014; 56: 414–24.
    OpenUrlCrossRefPubMed
  16. 16.↵
    2. Schell JC,
    3. Olson KA,
    4. Jiang L,
    5. Hawkins AJ,
    6. van Vranken JG,
    7. Xie J, et al.
    A role for the mitochondrial pyruvate carrier as a repressor of the warburg effect and colon cancer cell growth. Mol Cell. 2014; 56: 400–13.
    OpenUrlCrossRefPubMed
  17. 17.↵
    2. Mishra P,
    3. Chan DC.
    Metabolic regulation of mitochondrial dynamics. J Cell Biol. 2016; 212: 379–87.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    2. Li J,
    3. Ren S,
    4. Piao HL,
    5. Wang F,
    6. Yin P,
    7. Xu C, et al.
    Integration of lipidomics and transcriptomics unravels aberrant lipid metabolism and defines cholesteryl oleate as potential biomarker of prostate cancer. Sci Rep. 2016; 6: 20984.
  19. 19.↵
    2. Ren S,
    3. Shao Y,
    4. Zhao X,
    5. Hong CS,
    6. Wang F,
    7. Lu X, et al.
    Integration of metabolomics and transcriptomics reveals major metabolic pathways and potential biomarker involved in prostate cancer. Mol Cell Proteomics. 2016; 15: 154–63.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    2. Ren S,
    3. Wei GH,
    4. Liu D,
    5. Wang L,
    6. Hou Y,
    7. Zhu S, et al.
    Whole-genome and transcriptome sequencing of prostate cancer identify new genetic alterations driving disease progression. Eur Urol. 2017; 73: 322–39.
    OpenUrl
  21. 21.↵
    2. Cao Z,
    3. Ji J,
    4. Zhang C,
    5. Wang F,
    6. Xu H,
    7. Yu Y, et al.
    The preoperative neutrophil-to-lymphocyte ratio is not a marker of prostate cancer characteristics but is an independent predictor of biochemical recurrence in patients receiving radical prostatectomy. Cancer Med. 2019; 8: 1004–12.
    OpenUrl
  22. 22.↵
    2. Cookson MS,
    3. Aus G,
    4. Burnett AL,
    5. Canby-Hagino ED,
    6. D’Amico AV,
    7. Dmochowski RR, et al.
    Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: The American urological association prostate guidelines for localized prostate cancer update panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol. 2007; 177: 540–5.
    OpenUrlCrossRefPubMedWeb of Science
  23. 23.↵
    2. Cao K,
    3. Lei X,
    4. Liu H,
    5. Zhao H,
    6. Guo J,
    7. Chen Y, et al.
    Polydatin alleviated radiation-induced lung injury through activation of Sirt3 and inhibition of epithelial-mesenchymal transition. J Cell Mol Med. 2017; 21: 3264–76.
    OpenUrl
  24. 24.↵
    2. Rogatzki MJ,
    3. Ferguson BS,
    4. Goodwin ML,
    5. Gladden LB.
    Lactate is always the end product of glycolysis. Front Neurosci. 2015; 9: 22.
    OpenUrlCrossRefPubMed
  25. 25.↵
    2. Shoshan-Barmatz V,
    3. Mizrachi D.
    VDAC1: from structure to cancer therapy. Front Oncol. 2012; 2: 164.
    OpenUrlCrossRefPubMed
  26. 26.↵
    2. Bravo-Sagua R,
    3. Parra V,
    4. Lopez-Crisosto C,
    5. Diaz P,
    6. Quest AF,
    7. Lavandero S.
    Calcium transport and signaling in mitochondria. Compr Physiol. 2017; 7: 623–34.
    OpenUrl
  27. 27.↵
    2. Fulop L,
    3. Szanda G,
    4. Enyedi B,
    5. Varnai P,
    6. Spat A.
    The effect of OPA1 on mitochondrial CA2+ signaling. PLoS One. 2011; 6: e25199.
  28. 28.↵
    2. Weisthal S,
    3. Keinan N,
    4. Ben-Hail D,
    5. Arif T,
    6. Shoshan-Barmatz V.
    Ca(2+)-mediated regulation of VDAC1 expression levels is associated with cell death induction. Biochim Biophys Acta. 2014; 1843: 2270–81.
    OpenUrlCrossRef
  29. 29.↵
    2. Pfeiffer T,
    3. Schuster S,
    4. Bonhoeffer S.
    Cooperation and competition in the evolution of ATP-producing pathways. Science. 2001; 292: 504–7.
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    2. Young CD,
    3. Anderson SM.
    Sugar and fat - that’s where it’s at: metabolic changes in tumors. Breast Cancer Res. 2008; 10: 202.
    OpenUrlCrossRefPubMed
  31. 31.↵
    2. DeBerardinis RJ,
    3. Lum JJ,
    4. Hatzivassiliou G,
    5. Thompson CB.
    The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008; 7: 11–20.
    OpenUrlCrossRefPubMedWeb of Science
  32. 32.↵
    2. Vander Heiden MG,
    3. Cantley LC,
    4. Thompson CB.
    Understanding the warburg effect: the metabolic requirements of cell proliferation. Science. 2009; 324: 1029–33.
    OpenUrlAbstract/FREE Full Text
  33. 33.↵
    2. Cui J,
    3. Quan M,
    4. Xie D,
    5. Gao Y,
    6. Guha S,
    7. Fallon MB, et al.
    A novel KDM5A/MPC-1 signaling pathway promotes pancreatic cancer progression via redirecting mitochondrial pyruvate metabolism. Oncogene. 2020; 39: 1140–51.
    OpenUrl
  34. 34.↵
    2. Papandreou I,
    3. Cairns RA,
    4. Fontana L,
    5. Lim AL,
    6. Denko NC.
    HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab. 2006; 3: 187–97.
    OpenUrlCrossRefPubMedWeb of Science
  35. 35.↵
    2. Tang XP,
    3. Chen Q,
    4. Li Y,
    5. Wang Y,
    6. Zou HB,
    7. Fu WJ, et al.
    Mitochondrial pyruvate carrier 1 functions as a tumor suppressor and predicts the prognosis of human renal cell carcinoma. Lab Invest. 2019; 99: 191–9.
    OpenUrl
  36. 36.↵
    2. Hsu WK,
    3. Virk MS,
    4. Feeley BT,
    5. Stout DB,
    6. Chatziioannou AF,
    7. Lieberman JR.
    Characterization of osteolytic, osteoblastic, and mixed lesions in a prostate cancer mouse model using 18F-FDG and 18F-fluoride PET/CT. J Nucl Med. 2008; 49: 414–21.
    OpenUrlAbstract/FREE Full Text
  37. 37.↵
    2. Morris MJ,
    3. Akhurst T,
    4. Larson SM,
    5. Ditullio M,
    6. Chu E,
    7. Siedlecki K, et al.
    Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy. Clin Cancer Res. 2005; 11: 3210–6.
    OpenUrlAbstract/FREE Full Text
  38. 38.↵
    2. Hara T,
    3. Bansal A,
    4. DeGrado TR.
    Effect of hypoxia on the uptake of [methyl-3H]choline, [1-14C] acetate and [18F]FDG in cultured prostate cancer cells. Nucl Med Biol. 2006; 33: 977–84.
    OpenUrlCrossRefPubMed
  39. 39.↵
    2. Schlaepfer IR,
    3. Glode LM,
    4. Hitz CA,
    5. Pac CT,
    6. Boyle KE,
    7. Maroni P, et al.
    Inhibition of lipid oxidation increases glucose metabolism and enhances 2-Deoxy-2-[(18)F]Fluoro-D-Glucose uptake in prostate cancer mouse Xenografts. Mol Imaging Biol. 2015; 17: 529–38.
    OpenUrl
  40. 40.↵
    2. Rauckhorst AJ,
    3. Gray LR,
    4. Sheldon RD,
    5. Fu X,
    6. Pewa AD,
    7. Feddersen CR, et al.
    The mitochondrial pyruvate carrier mediates high fat diet-induced increases in hepatic TCA cycle capacity. Mol Metab. 2017; 6: 1468–79.
    OpenUrl
  41. 41.↵
    2. Xu H,
    3. Li S,
    4. Sun Y,
    5. Xu L,
    6. Hong X,
    7. Wang Z, et al.
    ELOVL5-mediated long chain fatty acid elongation contributes to enzalutamide resistance of prostate cancer. Cancers. 2021; 13: 3957.
    OpenUrl
  42. 42.↵
    2. Vasileiou PVS,
    3. Evangelou K,
    4. Vlasis K,
    5. Fildisis G,
    6. Panayiotidis MI,
    7. Chronopoulos E, et al.
    Mitochondrial homeostasis and cellular senescence. Cells. 2019; 8: 686.
    OpenUrl
  43. 43.↵
    2. Magri A,
    3. Di Rosa MC,
    4. Orlandi I,
    5. Guarino F,
    6. Reina S,
    7. Guarnaccia M, et al.
    Deletion of voltage-dependent anion channel 1 knocks mitochondria down triggering metabolic rewiring in yeast. Cell Mol Life Sci. 2020; 77: 3195–213.
    OpenUrl
  44. 44.↵
    2. Mazure NM.
    VDAC in cancer. Biochim Biophys Acta Bioenerg. 2017; 1858: 665–73.
    OpenUrl
  45. 45.↵
    2. Pedersen PL.
    Voltage dependent anion channels (VDACS): a brief introduction with a focus on the outer mitochondrial compartment’s roles together with hexokinase-2 in the “Warburg effect” in cancer. J Bioenerg Biomembr. 2008; 40: 123–6.
    OpenUrlCrossRefPubMedWeb of Science
  46. 46.↵
    2. Shoshan-Barmatz V,
    3. Israelson A,
    4. Brdiczka D,
    5. Sheu SS.
    The voltage-dependent anion channel (VDAC): function in intracellular signalling, cell life and cell death. Curr Pharm Des. 2006; 12: 2249–70.
    OpenUrlCrossRefPubMedWeb of Science
  47. 47.↵
    2. Shoshan-Barmatz V,
    3. De Pinto V,
    4. Zweckstetter M,
    5. Raviv Z,
    6. Keinan N,
    7. Arbel N.
    VDAC, a multi-functional mitochondrial protein regulating cell life and death. Mol Aspects Med. 2010; 31: 227–85.
    OpenUrlCrossRefPubMedWeb of Science
  48. 48.↵
    2. Song Z,
    3. Chen H,
    4. Fiket M,
    5. Alexander C,
    6. Chan DC.
    OPA1 processing controls mitochondrial fusion and is regulated by mRNA splicing, membrane potential, and Yme1L. J Cell Biol. 2007; 178: 749–55.
    OpenUrlAbstract/FREE Full Text
  49. 49.
    2. Baricault L,
    3. Segui B,
    4. Guegand L,
    5. Olichon A,
    6. Valette A,
    7. Larminat F, et al.
    OPA1 cleavage depends on decreased mitochondrial ATP level and bivalent metals. Exp Cell Res. 2007; 313: 3800–8.
    OpenUrlCrossRefPubMedWeb of Science
  50. 50.
    2. Cipolat S,
    3. Rudka T,
    4. Hartmann D,
    5. Costa V,
    6. Serneels L,
    7. Craessaerts K, et al.
    Mitochondrial rhomboid PARL regulates cytochrome c release during apoptosis via OPA1-dependent cristae remodeling. Cell. 2006; 126: 163–75.
    OpenUrlCrossRefPubMedWeb of Science
  51. 51.↵
    2. Arnoult D,
    3. Grodet A,
    4. Lee YJ,
    5. Estaquier J,
    6. Blackstone C.
    Release of OPA1 during apoptosis participates in the rapid and complete release of cytochrome c and subsequent mitochondrial fragmentation. J Biol Chem. 2005; 280: 35742–50.
    OpenUrlAbstract/FREE Full Text
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords